Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: A subgroup analysis within a noninferiority randomized controlled trial

British Journal of Dermatology

Volumn 172, Issue 3, 2015, Pages 739-745

  Roozeboom, M H ^a,b   Nelemans, P J ^c   Mosterd, K ^a,b   Steijlen, P M ^a,b   Arits, A H M M ^a,b   Kelleners Smeets, N W J ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; FLUOROURACIL; IMIQUIMOD; AMINOLEVULINIC ACID; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; METHYL 5-AMINOLEVULINATE; OINTMENT; PHOTOSENSITIZING AGENT;

ADULT; ARTICLE; ATTRIBUTABLE RISK; BASAL CELL CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL CANCER; TREATMENT OUTCOME; TRUNK; TUMOR RECURRENCE; TUMOR VOLUME; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, BASAL CELL; CLINICAL TRIAL; COMPARATIVE STUDY; INTRADERMAL DRUG ADMINISTRATION; OINTMENT; PHOTOCHEMOTHERAPY; PROCEDURES; SINGLE BLIND PROCEDURE; SKIN NEOPLASMS; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SINGLE-BLIND METHOD; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84925270542     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13299     Document Type: Article

References (21)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F,. A systematic review of worldwide incidence of non-melanoma skin cancer. Br J Dermatol 2012; 166: 1069-80.
2. Flohil SC, de Vries E, Neumann HA, et al,. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91: 24-30.
3. Housman TS, Feldman SR, Williford PM, et al,. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003; 48: 425-9.
4. Bath-Hextall FJ, Perkins W, Bong J, et al,. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007: CD003412.
5. Telfer NR, Colver GB, Morton CA,. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
6. Braathen LR, Szeimies RM, Basset-Seguin N, et al,. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Am Acad Dermatol 2007; 56: 125-43.
7. Arits AH, Mosterd K, Essers BA, et al,. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14: 647-54.
8. Arits AH, Spoorenberg E, Mosterd K, et al,. Cost-effectiveness of topical imiquimod and fluorouracil versus photodynamic therapy for treatment of superficial basal-cell carcinoma. Br J Dermatol 2014; doi: 10.1111/bjd.13066.
9. Roozeboom MH, Arits AH, Nelemans PJ, et al,. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol 2012; 167: 733-56.
10. Bath-Hextall F, Ozolins M, Armstrong SJ, et al,. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 15: 96-105.
11. Szeimies RM, Ibbotson S, Murrell DF, et al,. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008; 22: 1302-11.
12. Gupta AK, Cherman AM, Tyring SK,. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg 2004; 8: 338-52.
13. Choudhary S, Nouri K, Elsaie ML,. Photodynamic therapy in dermatology: a review. Lasers Med Sci 2009; 24: 971-80.
14. Oertelt-Prigione S,. The influence of sex and gender on the immune response. Autoimmun Rev 2012; 11: A479-85.
15. Trenova AG, Slavov GS, Manova MG, et al,. Female sex hormones and cytokine secretion in women with multiple sclerosis. Neurol Res 2013; 35: 95-9.
16. Fantini F, Greco A, Del Giovane C, et al,. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25: 896-901.
17. Christensen E, Mork C, Skogvoll E,. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. Br J Dermatol 2012; 166: 1342-8.
18. Li Q, Gao T, Jiao B, et al,. Tumor thickness predicts long-term complete response of facial basal cell carcinomas in Asian skin types iv/v treated with methyl aminolaevulinate photodynamic therapy. Photomed Laser Surg 2011; 29: 501-7.
19. Vinciullo C, Elliott T, Francis D, et al,. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152: 765-72.
20. Geisse J, Caro I, Lindholm J, et al,. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33.
21. Gollnick H, Barona CG, Frank RG, et al,. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15: 374-81.